GVS (GVS) Q3 2025 earnings summary

Executive summary

• Consolidated revenues for the first nine months of 2025 were €315.6 million, stable at constant exchange rates, with growth in Safety and Transfusion Medicine offsetting declines in MedTech and Energy & Mobility.

• Adjusted EBITDA increased 0.8% to €78.7 million, with margin improving to 24.9%, up 67 basis points year-over-year.

• Adjusted net profit (excluding FX) rose 7.2% to €36.3 million, with margin up to 11.5% from 10.5%.

• Net financial debt stood at €271.8 million as of September 2025, with a leverage ratio of 2.5x post-M&A and buybacks.

• The Haemonetics whole blood acquisition was completed in January 2025, strengthening Transfusion Medicine.

Financial highlights

• Revenue for 9M 2025 was €315.6 million, down 1.9% year-over-year, but up 0.2% at constant exchange rates.

• Adjusted EBITDA was €78.7 million, margin 24.9%, up 67 basis points year-over-year.

• Adjusted net income margin improved to 11.5% from 10.5% year-over-year.

• Net financial debt increased by €52.0 million from year-end 2024, mainly due to M&A and investments.

• Cash flow from operations was €28.7 million, down from €60.0 million in 2024, impacted by working capital and acquisitions.

Outlook and guidance

• FY 2025 guidance projects low single-digit revenue growth at constant exchange rates and adjusted EBITDA margin up 100–150 basis points versus FY 2024.

• Leverage ratio is expected to improve to 2.2x by year-end 2025, including buyback impact.

• FY 2026 outlook anticipates growth in MedTech, Life Sciences, and Transfusion Medicine, with new product launches and distributor agreements; Safety and Mobility divisions expect stable or growing revenues, especially in EV and hydrogen applications.